Variable effects of exposure to formulated microbicides on antibiotic susceptibility in firmicutes and proteobacteria by Forbes, Sarah et al.
Variable effects of exposure to formulated microbicides on 
antibiotic susceptibility in firmicutes and proteobacteria
FORBES, Sarah, KNIGHT, Christopher G., COWLEY, Nicola L., AMÉZQUITA, 
Alejandro, MCCLURE, Peter, HUMPHREYS, Gavin, MCBAIN, Andrew J. and 
DRAKE, H. L.
Available from Sheffield Hallam University Research Archive (SHURA) at:
http://shura.shu.ac.uk/14497/
This document is the author deposited version.  You are advised to consult the 
publisher's version if you wish to cite from it.
Published version
FORBES, Sarah, KNIGHT, Christopher G., COWLEY, Nicola L., AMÉZQUITA, 
Alejandro, MCCLURE, Peter, HUMPHREYS, Gavin, MCBAIN, Andrew J. and 
DRAKE, H. L. (2016). Variable effects of exposure to formulated microbicides on 
antibiotic susceptibility in firmicutes and proteobacteria. Applied and Environmental 
Microbiology, 82 (12), 3591-3598. 
Repository use policy
Copyright © and Moral Rights for the papers on this site are retained by the 
individual authors and/or other copyright owners. Users may download and/or print 
one copy of any article(s) in SHURA to facilitate their private study or for non-
commercial research. You may not engage in further distribution of the material or 
use it for any profit-making activities or any commercial gain.
Sheffield Hallam University Research Archive
http://shura.shu.ac.uk
Variable Effects of Exposure to Formulated 1 
Microbicides on Antibiotic Susceptibility in 2 
Firmicutes and Proteobacteria 3 
 4 
 5 
Sarah Forbes1, Christopher G Knight2, Nicola L Cowley1, Alejandro Amézquita3, 6 Peter McClure3, Gavin Humphreys1 and Andrew J McBain1* 7 
 8 
1Manchester Pharmacy School and 2Faculty of Life Sciences,  9 
The University of Manchester, Manchester, UK. 10 
3Unilever Safety and Environmental Assurance Centre,  11 
Colworth Science Park, Bedford UK. 12 
 13 
 14 
 15 
 16 
Key words Microbicides, biocides, antibiotics, susceptibility, resistance, formulation. 17 
Running titleμ Antibiotic susceptibility following exposure to microbicides 18 
 19 
 20 
 21 
 22 
 23 
 24 
 25 
 26 
 27 
 28 
 29 
*For correspondenceμ Andrew McBain, Manchester Pharmacy School, The University of Manchester, 30 
Oxford Road, Manchester M13 λPT, UK. Telμ 44 161 275 2360; Faxμ 44(0)161 275 23λ6; Emailμ 31 
andrew.mcbain@manchester.ac.uk  32 
ABSTRACT 33 
Microbicides are broad-spectrum antimicrobial agents that generally interact with multiple 34 
pharmacological targets. Whilst they are widely deployed in disinfectant, antiseptic and 35 
preservative formulations, data relating to their potential to select for microbicide or antibiotic 36 
resistance have been generated mainly by testing the compounds in much simpler aqueous 37 
solutions. In the current investigation, antibiotic susceptibility was determined for bacteria 38 
that had previously exhibited decreased microbicide susceptibility following repeated 39 
exposure to microbicides either in formulation with sequestrants and surfactants or in simple 40 
aqueous solution. Statistically significant increases in antibiotic susceptibility occurred 41 
for 12% of bacteria after exposure to microbicides in formulation vs 20% after exposure to 42 
aqueous solutions, whilst 22% became significantly less susceptible to the antibiotics, 43 
regardless of formulation. Of the combinations of bacterium and antibiotic for which British 44 
Society for Antimicrobial Chemotherapy breakpoints are available, none became resistant. 45 
Linear modeling, taking into account phylogeny, microbicide, antibiotic and formulation 46 
identified small but significant effects of formulation that varied depending on bacterium and 47 
microbicide. Adaptation to formulated benzalkonium chloride in particular was more likely to 48 
increase antibiotic susceptibility than the simple aqueous solution. In conclusion, bacterial 49 
adaptation through repeated microbicide-exposure was associated with both increases and 50 
decreases in antibiotic susceptibility. Formulation of the microbicide to which the bacteria had 51 
previously adapted had an identifiable effect on antibiotic susceptibility but this was typically 52 
small relative to the differences observed among microbicides. Susceptibility changes 53 
resulting in resistance were not observed. 54 
 55 
INTRODUCTION 56 
Microbicides are broad-spectrum antimicrobial compounds that are widely deployed to 57 
control the growth of microorganisms or eliminate them. Applications include the control of 58 
biofouling and microbial contamination in industry (1) as well as clinical antisepsis  (2-4). 59 
They are also used extensively in the domestic environment as hygiene adjuncts and 60 
preservatives in a range of formulations including oral care products (5), hand sanitizers (6) 61 
and hard surface cleaners (7).  62 
The safety of certain microbicide applications has been questioned due to the possibility that 63 
long-term microbicide exposure could select for reduced antimicrobial susceptibility in 64 
bacteria (8-10). Reduced microbicide susceptibility has been reported for some combinations 65 
of bacterium and microbicide (11) and changes in bacterial susceptibility to chemically 66 
unrelated antimicrobials such as antibiotics or other microbicides have been reported 67 
following laboratory microbicide exposure (12, 13). The mechanisms involved in such cross-68 
resistance include selection for mutations in shared cellular target sites, upregulation of efflux 69 
pumps (14), reductions in cell permeability (15) and in some cases, sporulation (16).  70 
Evidence that microbicides can select for reduced microbicide susceptibility in the 71 
environment is limited, with the majority of reports relating to in vitro exposure (17). 72 
Similarly, little evidence has emerged to firmly link microbicide/antibiotic cross-resistance to 73 
microbicide use (18-21). The majority of studies aiming to better understand the potential 74 
risks of resistance through microbicide exposure have exposed bacteria to microbicides in 75 
aqueous solution with or without the addition of co-solvents such as dimethyl sulfoxide (22) 76 
or ethanol (23). In real use however, microbicides are deployed in products formulated with 77 
surfactants, sequestrants and other compounds that can interact with cellular targets to 78 
influence antimicrobial potency. As previously reported, such formulation can decrease the 79 
frequency and extent of the acquisition of reduced microbicide susceptibility in bacteria (24). 80 
Accordingly, evaluating the effects of bacterial exposure to microbicides within a formulation 81 
chassis containing surfactants and sequestrants may generate more realistic data on which to 82 
base risk assessments on the induction of changes in bacterial susceptibility. In the current 83 
investigation we have therefore assessed changes in antibiotic susceptibility in bacteria which 84 
have previously exhibited decreases in microbicide susceptibility following repeated exposure 85 
to a range of microbicides in simple aqueous solutions and in formulations containing 86 
commonly used non-ionic surfactants and sequestrants (24). The microbicides tested reflect 87 
those frequently used in consumer products such as laundry detergents, hard surface 88 
disinfectants and personal care products. The antibiotics were selected on the basis of their 89 
common therapeutic use and their inclusion in a US investigation of links between domestic 90 
microbicide use and antibiotic resistance (25). 91 
MATERIALS AND METHODS 92 
Bacteria. Pseudomonas aeruginosa ATCC λ027, Staphylococcus aureus ATCC 6538, 93 
and Escherichia coli ATCC 25λ22 were obtained from Oxoid (Basingstoke, United 94 
Kingdom). Acinetobacter baumannii MBRG15.1, Pseudomonas putida MBRG15.2, 95 
Escherichia coli MBRG15.4 and Cronobacter sakazakii MBRG15.5, were isolated from a 96 
domestic kitchen drain biofilm. Enterococcus faecalis MRBG15.6 is a wound isolate provided 97 
by Angela Oates, The University of Manchester.  98 
Chemicals reagents and growth media. Bacteriological growth media were 99 
purchased from Oxoid (Basingstoke, United Kingdom). All other chemical reagents were 100 
purchased from Sigma-Aldrich (Dorset, United Kingdom) unless otherwise stated. Bacterial 101 
growth media were sterilized at 121°C and 15 lb/in2 for 15 min prior to use. Pseudomonas 102 
aeruginosa, Staphylococcus aureus, Escherichia coli, and Enterococcus faecalis were 103 
cultured on Tryptone Soy agar and broth. Acinetobacter baumannii, Pseudomonas putida and 104 
Cronobacter sakazakii were grown on Wilkins Chalgren agar and broth containing 2% 105 
sucrose. All bacteria were incubated aerobically at 37°C for 18 h unless stated otherwise. 106 
Antimicrobials. The microbicides benzalkonium chloride (BAC), chlorhexidine 107 
digluconate (CHX 20% v/v), thymol and triclosan were purchased from Sigma-Aldrich 108 
(Dorset, UK). Didecyldimethyl ammonium chloride (DDAC 50% v/v) was purchased from 109 
Merck Millipore (Durham, UK). Vantocil (a 20% v/v aqueous solution of polyhexamethylene 110 
biguanide (PHMB) was obtained from Arch Chemicals Inc. (Manchester, UK). Glydant (1,3-111 
Dimethylol-5,5-dimethylhydantoin; DMDM hydantoin at 54% v/v) was obtained from Lonza 112 
(Bishops Stortford, UK) whilst benzisothiazolinone (BIT) was supplied by Unilever (Port 113 
Sunlight, UK). All microbicides were prepared in aqueous solution or added to a microbicide-114 
free formulation chassis containing sequestrants and surfactants as previously described (24), 115 
at concentrations reflective of their normal deployment in consumer products. BAC, CHX, 116 
DDAC, DMDM hydantoin, PHMB and thymol were prepared at 1% (v/v) in a general 117 
purpose cleaner. Triclosan was added to a laundry detergent at 0.0066% (w/v). 118 
Benzisothiazolinone was formulated into a laundry detergent at 0.02% (v/v). Ciprofloxacin 119 
(1ȝg), cephalothin (20ȝg), ampicillin (10ȝg), kanamycin (5ȝg) and tetracycline (10ȝg) 120 
antibiotic discs were obtained from Oxoid (Basingstoke, UK). 121 
16S rRNA gene sequencing. Single bacterial colonies were dispersed in 100ȝl of 122 
nanopure water, vortexed for 30 sec. and boiled at 100˚C for 15min. to lyse cells. 123 
Microcentrifuge tubes were centrifuged at 16, 000 x g for 1 min to remove cellular debris and 124 
the resulting supernatant was retained as DNA template. PCR was performed using the 125 
primers 8FLP (5’-GAG TTT GAT CCT GGS TCA G-3’) and 806R (5’-GGA CTA CCA 126 
GGG TAT CTA AT-3’) at 5ȝM per reaction. PCR was conducted using a Biometra 127 
TGradient thermocycler (Analytik Jena, Germany) and run for 35 thermal cyclesμ λ4˚C (1 128 
min), 53˚C (1 min) and 72˚C (1min). A 15 min. elongation step was included in the final 129 
cycle. PCR products were purified using a QIAquick PCR purification kit (Qiagen, West 130 
Sussex, UK) according to manufacturer’s instructions and the resulting DNA yield was 131 
quantified using a NanoDrop 2000c UV-vis spectrophotometer (Thermo Scientific, 132 
Wilmington, USA). A reaction mixture containing 4pM forward or reverse primer and 40-133 
50ng of DNA in 10ȝl total volume was used for DNA sequencing. DNA sequencing was 134 
performed using the Applied Biosystems 3730 DNA Analyzer (ThermoFisher, Paisley, UK). 135 
Microbicide exposure in aqueous solution and formulation.  A system previously 136 
validated as highly selective for changes in antimicrobial susceptibility (26, 27) was used. 137 
Reproducible c. 100-fold-concentration gradients of the antimicrobial compounds were 138 
generated on Tryptone Soy or Wilkins Chalgren agar plates using an automated spiral plater 139 
(Don Whitley Scientific, Shipley, United Kingdom). Antimicrobials in aqueous solution or in 140 
formulation (50ȝl) were deposited on the agar surface. Plates were dried for 1h at room 141 
temperature prior to radial deposition of bacterial pure cultures and then incubated (4d; 37°C) 142 
in an aerobic incubator. After incubation, growth observed at the highest microbicide 143 
concentration was aseptically removed and streaked onto a fresh plate containing the same 144 
antimicrobial compound concentration gradient. Where growth was observed across the 145 
whole antimicrobial gradient, a new plate produced with a 5-fold-higher microbicide 146 
concentration was used. This process was repeated until 14 passages had occurred (P14). 147 
Bacteria at P0 and P14 were archived for subsequent susceptibility testing.   148 
Determination of antibiotic susceptibility. Bacteria showing ≥4-fold increases in 149 
minimum bactericidal concentration (MBC) after microbicide/formulation exposure were 150 
investigated for changes in antibiotic susceptibility. Antibiotic susceptibilities were 151 
determined for ciprofloxacin (1ȝg), cephalothin (20ȝg), ampicillin (10ȝg), kanamycin (5ȝg) 152 
and tetracycline (10ȝg). Disc diffusion assays were performed according to the British 153 
Society for Antimicrobial Chemotherapy (BSAC) disc diffusion method for antimicrobial 154 
susceptibility testing (28). 155 
Statistical analyses. Antibiotic zone of inhibition sizes were compared before and 156 
after adaptation to microbicides using Mann-Whitney U tests and in the cross-resistance 157 
assays using linear mixed effect models (LMMs). LMMs were required to simultaneously 158 
compare and account for the effects on the inhibition zone ofμ a) microbicidal environment to 159 
which the bacterium was adapted, b) the antibiotic against which it was tested and c) the 160 
interaction of microbicidal environment and antibiotic (each fitted as fixed effects) plus d) the 161 
different bacteria (fitted as a random effect), allowing the variation among bacteria to differ 162 
for different antibiotics. Initial models with this structure violated the statistical assumptions 163 
of normality of residuals and homogeneity of variance. Box-Cox transformation indicated that 164 
a transformation with a power of 0.5 (square root) was approximately optimal to address the 165 
non-normality and was therefore used. A wide range of different models accounting for non-166 
homogeneity of variance in response to different variables was tested. Models allowing 167 
different variances for different bacteria and different variances for different microbicidal 168 
environments were superior to all others tested (lowest Akaike information criterion). To 169 
account for the fact that closely related bacteria are likely to respond more similarly than 170 
others just through having a more recent common ancestor, a correlation term was included 171 
based on the 16S-based phylogenetic tree of the strains used. Testing different weightings on 172 
this correlation term (Pagel’s Ȝ (2λ)) determined that a Brownian model (i.e. Pagel’s Ȝ = 1) 173 
was best. In addition, a LMM was fitted for the subset of data involving microbicides where 174 
bacteria were tested that had adapted to both formulated and unformulated versions of the 175 
microbicidal environment. In this case, accounting for non-homogenous variance was best 176 
done by allowing different variances for different microbicidal environments and for variance 177 
to increase at higher values according to the formula e(0.65 * zone of clearance value). All models were 178 
fitted using the NLME package (Version 3.1) (30) in R version 3.2 (31) with phylogenetic 179 
correlation structures created using the APE package (version 3.3) (32). Where p-values are 180 
not explicitly given, statistical significance was deemed to be p< 0·05. 181 
RESULTS 182 
After exposure to microbicides in simple aqueous solution, out of λ0 possible combinations of 183 
bacterium and antibiotic, 22% significantly (P < 0.05) reduced in antibiotic susceptibility (8% 184 
towards ciprofloxacin, 6% to ampicillin, 4% to kanamycin, 2% to tetracycline and 2% to 185 
cephalothin). In comparison, 20% significantly increased in antibiotic susceptibility (6% 186 
towards ciprofloxacin, 4% to kanamycin, 4% to tetracycline, 3% to cephalothin and 2% to 187 
ampicillin). After exposure to the formulated microbicides, out of 50 possible combinations of 188 
bacterium and antibiotic, 22% significantly decreased in antibiotic susceptibility (6% 189 
ciprofloxacin, 6% kanamycin, 4% cephalothin and 4% tetracycline and 2% ampicillin). In 190 
comparison, 12% significantly increased in antibiotic susceptibility (8% ciprofloxacin 2% 191 
kanamycin and 2% tetracycline). Importantly, whilst statistically significant increases and 192 
decreases in antibiotic susceptibility occurred, generation of resistance as defined by BSAC 193 
breakpoints was not observed in any previously susceptible bacterium. 194 
The frequency of reduction in antibiotic susceptibility was highest in organisms exhibiting 195 
previously reduced susceptibility towards DMDM hydantoin (80%), followed by BAC, CHX, 196 
DDAC (20%), triclosan (20%) and PHMB (16%). Bacteria with reduced susceptibility to 197 
triclosan showed the highest frequency of increased antibiotic susceptibility (45%), followed 198 
by CHX (30%), DDAC (27%), DMDM hydantoin (20%) and PHMB (4%). In comparison, 199 
after exposure to the formulations, 27% of thymol formulation and 20% of DDAC 200 
formulation-adapted isolates exhibited increased antibiotic susceptibility, whilst 40% of 201 
DDAC formulation, 33% of thymol formulation, 10% of BAC formulation and 7% of PHMB 202 
formulation-adapted bacteria had significantly decreased antibiotic susceptibility. The 203 
following section details the effects of each microbicide on antibiotic susceptibility. 204 
Benzalkonium chloride. When comparing unexposed to BAC-adapted organisms 205 
there was a significant decrease in susceptibility of S. aureus to ciprofloxacin and kanamycin 206 
(Table 1). E. coli also showed a significant reduction in kanamycin susceptibility after 207 
exposure to BAC. After repeated exposure to BAC formulation S. aureus showed a 208 
significantly decreased susceptibility to ciprofloxacin (Table 1). 209 
 Chlorhexidine. S. aureus showed a significant decrease in susceptibility to ampicillin 210 
and ciprofloxacin after CHX exposure as well as an increase in susceptibility to tetracycline 211 
(Table 1). E. coli demonstrated increased susceptibility to ciprofloxacin and ampicillin after 212 
repeated exposure to chlorhexidine. 213 
Didecydimethyl ammonium chloride. After exposure to DDAC, A. baumanii 214 
showed a significant increase in susceptibility to ciprofloxacin and kanamycin and decreased 215 
susceptibility to tetracycline when compared to the bacterium before microbicide exposure 216 
(Table 1). Increased susceptibility to ciprofloxacin, kanamycin and cephalothin was observed 217 
for the E. coli drain isolate, whilst a significant reduction in tetracycline susceptibility was 218 
also evident in this bacterium. After exposure to DDAC in formulation, the E. coli drain 219 
isolate underwent a significant reduction in kanamycin, cephalothin, tetracycline and 220 
ampicillin susceptibility, and an increase in susceptibility to ciprofloxacin. P. aeruginosa 221 
showed a significant increase in ciprofloxacin susceptibility after long-term exposure to 222 
DDAC formulation (Table 1). 223 
DMDM hydantoin. After repeated exposure to DMDM hydantoin the E. coli drain 224 
isolate demonstrated a significant reduction in ciprofloxacin, kanamycin, cephalothin and 225 
ampicillin susceptibility and an increase in tetracycline susceptibility when compared to its 226 
pre-exposed counterpart (Table 1).  227 
Polyhexamethylene biguanide. Following adaptation to PHMB, the E. coli drain 228 
isolate exhibited a decrease in kanamycin and ciprofloxacin susceptibility (Table 1). S. aureus 229 
developed a significantly reduced susceptibility to ampicillin and ciprofloxacin after repeated 230 
PHMB exposure but higher tetracycline susceptibility when compared to the unexposed 231 
parent strain. After exposure to PHMB formulation S. aureus also showed a significant 232 
reduction in ciprofloxacin susceptibility.  233 
Thymol. None of the test bacteria demonstrated a significant change in antibiotic 234 
susceptibility after exposure to thymol in aqueous solution. Following exposure to the 235 
thymol-containing formulation however, P. putida underwent significant decreases in 236 
susceptibility to ciprofloxacin and kanamycin (Table 1), whilst E. coli showed significant 237 
increases in ciprofloxacin and cephalothin susceptibility but decreases in susceptibility to 238 
kanamycin and tetracycline. A. baumanii increased in susceptibility to ciprofloxacin, 239 
kanamycin and tetracycline compared to its unexposed counterpart (Table 1).  240 
Triclosan. Following exposure to triclosan, S. aureus exhibited significant reductions 241 
in ciprofloxacin and ampicillin susceptibility whilst susceptibility to kanamycin, tetracycline 242 
and cephalothin increased (Table 1). E. coli showed increased susceptibility to ampicillin and 243 
ciprofloxacin for this bacterium after triclosan exposure, whilst the E. coli drain isolate 244 
showed decreased ciprofloxacin susceptibility but increased cephalothin susceptibility, when 245 
compared to the parent strain. Comparatively C. sakazakii showed a significant increase in 246 
ciprofloxacin, cephalothin and kanamycin susceptibility, and a decrease in ampicillin 247 
susceptibility after repeated triclosan exposure (Table 1).  248 
To gain an overview of the statistical significance of the observed changes in antibiotic 249 
susceptibility and ask whether it was possible to identify consistent patterns in susceptibility, 250 
linear mixed-effects models were fitted for how the susceptibility to particular antibiotics 251 
varied, dependent on the antibiotic in question, the bacterium and the microbicidal 252 
environment previously adapted to. A highly significant interaction (F40, 2λ8 = 15, P < 2 x 10-253 
16) indicative of different responses to particular antibiotics dependent on the microbicidal 254 
environment to which the organism had previously adapted (Fig. 1) was observed. Bacterial 255 
strains differed most in their response to ampicillin (standard deviation among strains = 5.1) 256 
and least in their response to tetracycline (standard deviation among strains = 2.7), with the 257 
responses of different strains to some antibiotics being associated either positively 258 
(cephalothin and ampicillin, r = 0.λ5) or negatively (ciprofloxacin and ampicillin, r = -0.28), 259 
(Table 2). 260 
Data presented in Fig. 1 indicate differences in the antibiotic susceptibility of organisms 261 
previously adapted to either formulated or unformulated microbicides. The differences in 262 
susceptibility changes observed between microbicides in simple aqueous solution or in 263 
complex formulation were highly significant (likelihood ratio test of the full model against a 264 
model treating formulated and unformulated versions of microbicides as equivalentμ LR88,70 = 265 
61, P = 8.6 x 10-10). To test whether there was any consistent effect of formulation; a second 266 
linear mixed-effects model was created for the subset of the data where strains had adapted to 267 
both formulated and unformulated versions of the same microbicide (PHMB, BAC and 268 
DDAC). This indicated that the way bacteria adapted to formulated versus non-formulated 269 
versions of a microbicide depended on the microbicide in question (F2, 145 = 4.5, P = 0.012), 270 
although that did not vary significantly among the antibiotics (F8, 145 = 0.70, P = 0.6λ). The 271 
effect of formulation was specific to BAC, with formulation giving a small increase in the 272 
antibiotic susceptibility of microbes adapted to it (Fig. 2). 273 
 274 
DISCUSSION 275 
Investigations into the potential of microbicides to select for reduced microbicide 276 
susceptibility in bacteria and induce cross-resistance to antibiotics have been largely 277 
conducted by evaluating susceptibility changes following exposure of bacteria to microbicides 278 
in simple aqueous solution (17). In such experiments, susceptibility of the exposed bacteria 279 
has been reported to decrease for certain combinations of bacterium and microbicide either 280 
transiently or stably (26). In the real world however microbicides are deployed in complex 281 
formulations containing sequestrants, surfactants and other compounds. Recent investigations 282 
indicate that the formulation of microbicides can significantly enhance antibacterial potency 283 
and that decreases in microbicide susceptibility after sub-lethal microbicide exposure may be 284 
significantly lower in frequency and extent when the microbicides are incorporated into 285 
formulations reflecting application in the real world (24, 33). This highlights the value of risk 286 
assessments that more accurately reflect the way microbicides are deployed. In the current 287 
investigation we have evaluated whether the formulation of microbicides additionally 288 
mitigates the development of antibiotic insusceptibility in bacteria. 289 
In order to investigate whether the formulation of microbicides affects cross-resistance to 290 
antibiotics, we studied the induction of changes in antibiotic susceptibility in bacteria that had 291 
been repeatedly exposed, using a highly selective system arguably representing a worst case 292 
scenario, to microbicides in simple aqueous solution and in formulation with ingredients that 293 
are used in consumer products such as laundry detergents, hard surface disinfectants and 294 
personal care products (24). It should be noted that whilst the majority of microbicides tested 295 
are widely used in domestic cleaning products, the use of triclosan in Europe is generally 296 
restricted to applications where its utility is greatest, such as oral care. 297 
Out of 288 microbicide-exposed bacteria, 28 organisms previously demonstrated a ≥4-fold 298 
decrease in microbicide susceptibility (18 organisms adapted to microbicides following 299 
exposure to simple aqueous solutions and 10 to microbicides in formulation). These were 300 
further evaluated for changes in antibiotic susceptibility in the current study. The difference in 301 
the numbers of test bacteria between treatment groups results from the mitigating effects that 302 
the formulation of microbicides had on the development of microbicide insusceptibility. 303 
Increases in antibiotic susceptibility occurred at higher frequency following exposure to 304 
simple solutions in comparison to formulations (20% v 12%) whilst 22% became significantly 305 
less susceptible to the antibiotics regardless of formulation. Whilst both increases and 306 
decreases in antibiotic susceptibility were observed in the test bacteria after exposure to 307 
microbicide/formulation, no bacterium became resistant according to published BSAC 308 
breakpoints.  309 
Changes in antibiotic susceptibility varied between the test antibiotics, bacteria and the 310 
microbicides that the bacteria had been previously adapted to, suggesting little correlative 311 
effect between the different variables. One positive correlation was however observed 312 
between the β-lactam antibiotics ampicillin and cephalothin (Table 2). In this case, 313 
microbicide exposure could have altered alteration transpeptidase expression or otherwise 314 
influenced cell wall permeability, subsequently impacting on the efficacy of these antibiotics 315 
which target cell wall synthesis.  316 
In some cases, bacterial antibiotic susceptibility was increased following microbicide 317 
exposure. It is notable that such “cross-susceptibility” was associated with adaptation to at 318 
least some microbicides for all antibiotics except ampicillin (Fig. 1). The phenomenon of 319 
“cross-susceptibility” has been observed in several previous investigations (17, 22, 34, 35) 320 
where links between antibiotics and decreased microbicide susceptibility in bacteria have 321 
been demonstrated in vitro (14, 17).  In a recent study, exposure of Burkholderia cepacia to 322 
low concentrations of either CHX or BAC resulted in variable reductions in antibiotic 323 
susceptibility (36). CHX exposure was reportedly associated with significant decreases in 324 
susceptibility to ceftazidime, ciprofloxacin and imipenem, whilst short-term exposure to BAC 325 
resulted in significant decreases in ceftazidime, ciprofloxacin and meropenem susceptibility. 326 
These effects were however highly variable between biological replicates in a manner 327 
suggestive of stochastic effects. In another recent investigation, six S. aureus strains including 328 
methicillin-resistant S. aureus were repeatedly exposed to triclosan. Susceptibility to triclosan 329 
was significantly decreased in all exposed bacteria, whereas antibiotic susceptibility was 330 
significantly increased in the majority of cases. Whilst the reasons for cross-susceptibility 331 
have not been elucidated, they are likely to include general fitness costs of adaptation and 332 
transient cellular damage as previously hypothesized (37).  333 
Mechanisms of cross-resistance have been more extensively investigated and include non-334 
specific reductions in cell permeability, active efflux of the compound from the bacterial cell 335 
or acquired mutations in shared target sites (14, 17). Antibiotics such as aminoglycosides 336 
enter the cell through a mechanism of self-promoted uptake (38) whereby they displace 337 
cations in the bacterial cell envelope leading to the reorganisation of lipopolysaccharide, 338 
which may facilitate antibiotic entry. This mechanism of self-promoted uptake mirrors that of 339 
polymeric biguanides, such as PHMB and CHX (3λ) which has led to the question as to 340 
whether any adaptation to reduce biguanide uptake may have a resulting effect on the uptake 341 
of aminoglycosides into the bacterial cell. The current investigation included the evaluation of 342 
any changes in susceptibility to the aminoglycoside antibiotic kanamycin in bacteria that had 343 
previously shown reduced susceptibility to both CHX and PHMB. However, we found no 344 
evidence of a systematic effect of this sort (indeed adaptation to CHX typically led to an 345 
increase in susceptibility to kanamycin; Fig. 1) and only the PHMB adapted E. coli drain 346 
isolate showed any significant reduction in antibiotic susceptibility (Table 1). 347 
Cross-resistance between quaternary ammonium compounds (QACs), such as BAC and 348 
DDAC and antibiotics has been attributed to the expression of broad-range efflux systems 349 
capable of removing both the microbicide as well as certain antibiotics from the bacterial cell 350 
(40-42). It has additionally been noted that genes encoding QAC-specific efflux pumps such 351 
as qacA/B may be detected on plasmids bearing β-lactamases in certain clinical isolates, 352 
suggesting another cause for correlation between QACs and penicillins, such as ampicillin 353 
(43). Furthermore, the qacE gene has been detected in the 3' conserved sequence of certain 354 
integrons found in multiple Gram-negative bacteria. Integrons often contain multiple 355 
antibiotic resistance genes, and due to their high mobility, may allow the dissemination of 356 
both QAC and antibiotic resistance genes through a population via horizontal gene transfer 357 
(44). Our data indicate that 20% of bacterial isolates with reduced BAC and DDAC 358 
susceptibility in addition to 40% and 10% of isolates with reduced DDAC or BAC 359 
formulation susceptibility, were also significantly reduced in their antibiotic susceptibility. 360 
Linear mixed effect modelling revealed that the formulation of BAC conferred a moderate 361 
protective effect on the development of antibiotic cross-resistance (Fig. 2), possibly 362 
suggesting a regulatory impact of the formulation excipients on the induction of the 363 
aforementioned efflux mechanisms, due to non-specific effects on cell permeability or 364 
through other cellular changes. 365 
Triclosan exposure may select for mutations in the target enzyme fabI, an enoyl-acyl carrier 366 
protein reductase that participates in bacterial fatty acid synthesis (45). There has been 367 
concern over the induction of cross-resistance between triclosan and therapeutic agents that 368 
also share this target enzyme, such as isoniazid used to treat Mycobacterium tuberculosis. 369 
Cross-resistance between triclosan and certain antibiotics has been reported in P. aeruginosa 370 
and is largely believed to be due to increased expression of the MexAB-OprM efflux system 371 
(14). In the current investigation, data show reductions in ciprofloxacin susceptibility in S. 372 
aureus and the E. coli drain isolate together with reductions in ampicillin susceptibility in S. 373 
aureus and C. sakazakii after repeated triclosan exposure, which may potentially be mediated 374 
through regulation of efflux or cell permeability.  375 
Whilst the induction of cross-resistance between microbicides and antibiotics has been 376 
previously investigated, little information is available concerning any effect of incorporation 377 
of microbicides into formulations containing surfactants and sequestrants on antibiotic 378 
susceptibility in adapted bacteria. Data presented here indicate that both decreases and 379 
increases in antibiotic susceptibility can occur in bacteria following exposure to microbicides 380 
in simple solution and in formulations using a highly selective system. A rigorous statistical 381 
analysis demonstrated that formulation significantly affected the development of cross-382 
resistance but that this was variable with the only consistently identified formulation effect 383 
being a small increase in susceptibility across antibiotics in strains adapted to the formulated, 384 
relative to the unformulated version of the microbicide benzalkonium chloride.  385 
In conclusion, whilst both increases and decreases in antibiotic susceptibility were observed in 386 
microbicide and formulation adapted bacteria, these were not sufficient to confer clinical 387 
resistance according to published BSAC breakpoints.  388 
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Table 1. Antibiotic susceptibility of bacterial isolates that showed a ≥ 4-fold decrease in microbicide/formulation susceptibility following exposure to microbicides in 
simple aqueous solution or formulated with surfactants and sequestrants.  
 
 
 
 
 
Microbicide 
 
 
 
 
 
Bacterium 
Ciprofloxacin 
 
Kanamycin 
 
Cephalothin 
 
Ampicillin 
 
 
Tetracycline 
 
UE UF F UE UF F UE UF F UE UF F UE UF F 
P0 P14 P14 P0 P14 P14 P0 P14 P14 P0 P14 P14 P0 P14 P14 
BAC S. aureus† 22 14 (0.5) 18 (0.5) 17 (1.5) 14 (0.6) 17 (0.5) 45 (0.5) 43 45 47 (0.5) 45 (0.5) 46 26 (0.5) 25 (0.5) 27 (0.5) 
E. coli† 29 (1.5) 31 31 (0.5) 15 (1.2) 12 (0.5) 14 (0.4) 18 (0.5) 16 (2.1) 18 21 22 (0.5) 21 21 (0.5) 21 (0.5) 20 (0.5) 
P. aeruginosa† 25 (1.5) 25 na ns ns na ns ns na ns ns na ns ns na 
                 
CHX S. aureus† 22 19 (0.5) na 17 (1.5) 18 na 45 (0.6) 45 (0.5) na 47 (0.5) 29 (1) na 26 (0.6) 35 (2.2) na 
E. coli† 29 (1.5) 35 (0.5) na 15 (1.2) 16 (0.5) na 18 (0.5) 20 (2.1) na 21 24 (0.5) na 21 (0.5) 23 (1.5) na 
                 
DDAC P. aeruginosa† 25 (1.5) 25 28 (0.6) ns ns ns ns ns ns ns ns ns ns ns ns 
A. baumanii* 19 27 na 19 21 na ns ns na ns ns na 15 13 na 
E. coli* 37 42 (1.5) 40 (0.6) 14 18 11 19 24 (2.1) 15 (0.5) 25 26 (1.5) 21 (0.6) 20 11 (0.5) 11 (0.5) 
                 
DMDM E. coli* 37 35 na 14 12 (1.5) na 19 16 na 25 20 (0.5) na 20 24 na 
                 
PHMB S. aureus† 22 20 (0.5) 21 17 (1.5) 17 (1.2) 16 (0.5) 45 (0.6) 45 (0.5) 45 47 (0.5) 35 (0.5) 45 (1.5) 26 (0.6) 36 (1.5) 25 (0.5) 
 E. coli† 29 (1.5) 29 na 15 (1.2) 16 (0.5) na 18 (0.5) 18 (2.1) na 21 20 (1.5) na 21 (0.5) 22 (0.5) na 
 P. aeruginosa† 25 (1.5) 25 25 (0.9) ns ns ns ns ns ns ns ns ns ns ns ns 
E. faecalis† ns ns ns ns ns ns 12 13 (0.5) 12 (0.5) 33 33 33 (1.3) 8 8 9 (0.5) 
E. coli * 37 28 (0.6) na 14 12 (1.5) na 19 18 (2.2) na 25 25 (0.5) na 20 20 (0.5) na 
Thymol E. coli†  29 (1.5) na 33 15 (1.2) na 14 18 (0.5) na 19 21 na 21 21 (0.5) na 20 
P. putida* 27 na 19.5 (0.5) 30 na 27 (0.5) ns na ns ns na ns 14 na 12 (2.1) 
A. baumanii* 19 na 33 (0.5) 19 na 22 ns na ns ns na ns 15 na 16 (0.5) 
Triclosan S. aureus† 22 21 (0.5) na 17 (1.5) 21 (0.5) na 45 (0.5) 51 (2.5) na 47 (0.5) 44 (0.5) na 26 (0.5) 34 na 
E. coli† 29 (1.5) 41 (1.5) na 15 (1.2) 13 (0.5) na 18 (0.5) 18 (0.5) na 21 28 (0.5) na 21 (0.6) 20 (1.5) na 
C. sakazakii* 28 32 (0.6) na 17 20 (0.5) na 11 12 na 25 21 (0.5) na 17 17 (0.5) na 
E. coli * 37 35 na 14 15 (1.3) na 19 20 na 25 24 (1.2) na 20 23 (2.1) na 
Data show growth inhibition zones (mm) representative of antibiotic susceptibility before (P0) and after 14 passages (P14) in the presence of microbicide/formulation.  Antibiotic zones of inhibition were determined before 
antimicrobial exposure (unexposed; UE) and after antimicrobial exposure to both unformulated (UF) (i.e. simple aqueoussolution) and formulated (F) (i.e. with surfactants and sequestrants) microbicides. †, non-drain isolates; *, 
drain isolates. Statistically significant changes are bold text (P < 0.05). Bacteria that did not undergo a ≥4-fold change in MBC were not assessed for changes in antibiotic susceptibility. Where data varied between biological 
replicates, standard deviations have been given in parentheses (n=6). Combinations of bacterium and antibiotic for which BSAC breakpoints are available are indicated in blue text. According to these, no susceptible bacterium 
became antibiotic resistant following microbicide adaptation. 
1 
Table 2. Correlation across strains in the responses to different antibiotics in the linear  
mixed effects model. 
 
 
 
 
 
 
 
AMP CEP CIP KAN TET 
AMP 1 0.95 -0.28 -0.08 0.54 
CEP 0.95 1 -0.09 0.03 0.61 
CIP -0.28 -0.09 1 0.54 0.17 
KAN -0.08 0.03 0.54 1 0.73 
TET 0.55 0.61 0.17 0.73 1 
Key:  
 
 
A value of 1 indicates that all organisms respond in a perfectly correlated way to the two 
antibiotics indicated (either more or less sensitive to both), a value of -1 would indicate a 
perfect negative correlation with organisms that are more sensitive to one antibiotic. Amp, 
ampicillin; cep, cephalothin; cip, ciprofloxacin; kan, kanamycin; tet, tetracycline. 
 


